Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
Launched by BAQIYATALLAH MEDICAL SCIENCES UNIVERSITY · Jun 27, 2008
Trial Information
Current as of May 25, 2025
Completed
Keywords
ClinConnect Summary
The investigators enroll 400 patients into the study. The patients receive PEGASYS (Peginterferon alpha-2a(40 KD)) 180 microgram per week plus COPEGUS (Ribavirin) 800 microgram for Genotype 2 and 3 and 1000 milligram for weight less than 75 kg and 1200 milligram for more than 75 kg. The duration of protocol is depends on genotypes of virus. In genotype 1 and 4, for 48 week and in genotypes 2 and 3 , for 24 weeks. The patients are visited every 4 weeks with biochemistry lab tests. The patients are checked with quantitative HCV RNA on the third months after initiation of the treatment to asse...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HCV RNA positive
- • Age older than 12 years
- Exclusion Criteria:
- • Ongoing pregnancy or breast feeding
- • Hx of HCC
- • Hx of alcoholic liver disease
- • Hx of bleeding from esophageal varices
- • Hx of hemochromatosis
- • Hx of autoimmune hepatitis
- • Hx of Suicidal attempt
- • Hx of cerebrovascular dis
- • Hx of severe retinopathy
- • Hx of severe psoriasis
- • Hx of scleroderma
- • Hx of metabolic liver disease
- • Hx of SLE
About Baqiyatallah Medical Sciences University
Baqiyatallah Medical Sciences University is a distinguished institution dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, the university emphasizes the integration of scientific inquiry and clinical practice, fostering an environment that supports the development of new therapies and medical technologies. With a commitment to ethical standards and patient safety, Baqiyatallah Medical Sciences University collaborates with a network of healthcare professionals and researchers to address pressing medical challenges, ultimately aiming to enhance patient outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
Professor Seyed-Moayed Alavian, Professor
Study Chair
Baqiyatallah Research Center for Gastroenterology and Liver Diseases
Seyyed Mohammad Miri, M.D.
Study Director
Baqiyatallah Research Center for Gastroenterology and Liver Diseases
Maryam Keshvari, M.D.
Principal Investigator
Iranian blood Transfusion Research Center
Bita Behnava, M.D.
Principal Investigator
Baqiyatallah Research Center for Gastroenterology and Liver Diseases
Mohammad Hossein Somi, M.D.
Principal Investigator
Research Center for Gastroenterology and Hepatology, Tabriz University of Medical Sciences, Tabriz
Fariborz Mansour-Ghanaei, M.D.
Principal Investigator
Gastroenterology and Liver Diseases, Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran
Pegah Karimi, M.D.
Principal Investigator
Baqiyatallah Research Center for Gastroenterology and Liver Diseases
Bashir HajiBeigi, M.D.
Principal Investigator
Iranian Blood Transfusion Research Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials